Hypertension and cardiovascular risk assessment in dialysis patients
Authors:
- Francesco LocatelliFLFrancesco Locatelli
- José LuñoJLJosé Luño
- Mohammed YaqoobMYMohammed Yaqoob
Open Access
- 5 March 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (5) , 1058-1068
Abstract
Introduction. Cardiovascular (CV) disease is the main cause of morbidity and mortality in dialysis patients. Hypertension in patients affected by chronic renal insufficiency (CRI) has been recognized as one of the major classical CV risk factors in CRI from the very beginning of the dialysis era. However, its treatment is still unsatisfactory. Methods. A discussion is employed to achieve a consensus on key points relating to the epidemiological, pathophysiological and clinical characteristics of hypertension in renal patients, in the light of global CV risk assessment. Results. CV disease is accelerated by CRI, in particular by uraemia-specific risk factors. This is reflected by the fact that general population-based equations for calculating CV risk underestimate the real CV risk in CRI and dialysis patients. Hypertension in dialysis patients is clearly a major CV risk factor. Isolated systolic hypertension with increased pulse pressure is the most prevalent blood pressure (BP) anomaly in dialysis patients, due to stiffening of the arterial tree. BP should be assessed by clinical measurements on a routine basis, leaving 24 h monitoring for selected cases. The targets of BP control should be those recommended by the present guidelines, i.e. Conclusions. Hypertension in renal patients has to be given particular and continued attention, and it should be adequately treated in light of the increased CV risk of this patient population. Research into the mechanisms of uraemic cardiomyopathy and cardiovascular remodelling should provide a precious new insight and lead to more precisely targeted and more effective therapies than in the past.Keywords
This publication has 62 references indexed in Scilit:
- Calpain is activated in experimental uremia: Is calpain a mediator of uremia-induced myocardial injury?Kidney International, 2003
- Improvement in Blood Pressure, Arterial Stiffness and Wave Reflections With a Very-Low-Dose Perindopril/Indapamide Combination in Hypertensive PatientHypertension, 2001
- Atherosclerotic cardiovascular disease risks in chronic hemodialysis patientsKidney International, 2000
- Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveformsKidney International, 2000
- Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patientsJournal Of Hypertension, 1999
- Treatment of hypertension in dialysis patients by ultrafiltration: Role of cardiac dilatation and time factorAmerican Journal of Kidney Diseases, 1999
- Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal ImpairmentHypertension, 1998
- Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal diseaseKidney International, 1996
- Carotid artery intima‐media thickness as an indicator of generalized atherosclerosisJournal of Internal Medicine, 1994
- Survival as an index of adequacy of dialysisKidney International, 1992